Clinical Trial Update: BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis [Phase 2]

View source ↗

Summary

Phase 2 trial update comparing BI 655066/ABBV-066 (risankizumab) to placebo in active psoriatic arthritis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Risankizumab (risankizumab)

Snippet

Sponsor: AbbVie | Conditions: Arthritis, Psoriatic | Phase 2 | Status: COMPLETED | Results posted: 2019-05-30